Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?

Group 1: Novavax Stock Performance - Novavax (NVAX) shares increased by 11.4% to close at $6.24, following a significant trading volume compared to normal sessions, despite a 28.8% loss over the past four weeks [1][2] - The stock price recovery is attributed to a rebound after an 8-session decline, with investors optimistic about a favorable FDA decision regarding the company's protein-based COVID-19 vaccine [2] Group 2: Financial Expectations - Novavax is projected to report a quarterly loss of$ 0.43 per share, reflecting a year-over-year increase of 59.1%, while revenues are expected to be $72.27 million, down 23% from the previous year [3] - The consensus EPS estimate for Novavax has been revised 7.6% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Group 3: Industry Context - Novavax operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Travere Therapeutics (TVTX), experienced a 9.5% decline to$ 14.99, with a -12.6% return over the past month [4] - Travere's consensus EPS estimate remains unchanged at -$0.54, representing a year-over-year change of 69.3% [5]